Clinical Data, Inc. (NASDAQ: CLDA), today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD). Viibryd is a new molecular entity and the first and only selective serotonin reuptake inhibitor and 5HT1A […]
Continue ReadingFDA Approval: Halaven
November 16, 2010
FDA Approves Eisai Inc. (ESALF.PK)’s Halaven For Late-Stage Breast Cancer 11/15/2010 SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. Breast cancer is the second leading […]
Continue ReadingFDA Pharmaceutical Approval: Glassia
August 12, 2010
Kamada Ltd. (KMDA.TA) received FDA Approval for AATD Drug Glassia. According to the Alpha-1 Association, Alpha-1 Antitrypsin Deficiency (Alpha-1) is a condition that is passed on from parents to their children through genes. This condition may result in serious lung and/or liver disease at various ages in life. Alpha-1 antitrypsin is a protein that is […]
Continue ReadingFDA Pharmaceutical Approval: Zuplenz
August 10, 2010
FDA Approves Strativa Pharmaceuticals’ Zuplenz (ondansetron) Oral Soluble Film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. “The FDA approval of Zuplenz marks an important milestone for Strativa as it reinforces our commitment to enhancing prescription products to meet the different needs of patients,” said John A. […]
Continue Reading